8.87
price down icon1.11%   -0.10
after-market After Hours: 8.85 -0.02 -0.23%
loading
Phathom Pharmaceuticals Inc stock is traded at $8.87, with a volume of 420.05K. It is down -1.11% in the last 24 hours and down -48.67% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$8.97
Open:
$8.9
24h Volume:
420.05K
Relative Volume:
0.33
Market Cap:
$606.51M
Revenue:
-
Net Income/Loss:
$-297.11M
P/E Ratio:
-2.0251
EPS:
-4.38
Net Cash Flow:
$-216.95M
1W Performance:
-5.03%
1M Performance:
-48.67%
6M Performance:
-12.00%
1Y Performance:
+24.93%
1-Day Range:
Value
$8.61
$9.0129
1-Week Range:
Value
$8.61
$9.5691
52-Week Range:
Value
$6.065
$19.71

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name
Name
Phathom Pharmaceuticals Inc
Name
Phone
(877) 742-8466
Name
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Name
Employee
112
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PHAT's Discussions on Twitter

Compare PHAT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PHAT
Phathom Pharmaceuticals Inc
8.87 606.51M 0 -297.11M -216.95M -5.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.13 120.56B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
750.22 82.44B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
616.55 36.87B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.07 32.64B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
118.39 28.38B 3.30B -501.07M 1.03B -2.1146

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date Action Analyst Rating Change
May-03-24 Initiated Stifel Buy
Jan-05-24 Reiterated Needham Buy
Aug-09-23 Initiated H.C. Wainwright Buy
May-11-23 Upgrade Evercore ISI In-line → Outperform
Mar-13-23 Initiated Craig Hallum Buy
Oct-21-22 Initiated Jefferies Buy
May-06-22 Downgrade Evercore ISI Outperform → In-line
May-12-21 Upgrade Goldman Sell → Neutral
Feb-17-21 Initiated BMO Capital Markets Outperform
Feb-02-21 Initiated Guggenheim Buy
Jun-26-20 Downgrade Goldman Neutral → Sell
Nov-20-19 Initiated Evercore ISI Outperform
Nov-19-19 Initiated Goldman Neutral
Nov-19-19 Initiated Jefferies Buy
Nov-19-19 Initiated Needham Buy
View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

pulisher
Dec 01, 2024

Wasatch Advisors LP Invests $4.47 Million in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.5%Should You Sell? - MarketBeat

Nov 30, 2024
pulisher
Nov 30, 2024

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Short Interest Update - MarketBeat

Nov 30, 2024
pulisher
Nov 25, 2024

Eagle Asset Management Inc. Increases Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat

Nov 25, 2024
pulisher
Nov 25, 2024

(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 25, 2024
pulisher
Nov 23, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownTime to Sell? - MarketBeat

Nov 23, 2024
pulisher
Nov 21, 2024

Jennison Associates LLC Has $106.06 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat

Nov 21, 2024
pulisher
Nov 20, 2024

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Phathom Pharmaceuticals - The Healthcare Technology Report.

Nov 19, 2024
pulisher
Nov 14, 2024

(PHAT) Proactive Strategies - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 11, 2024

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 11, 2024
pulisher
Nov 11, 2024

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Up 115.60% This Year: What Is Going To Happen Next - Stocks Register

Nov 11, 2024
pulisher
Nov 11, 2024

Phathom Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Business Updates - Defense World

Nov 11, 2024
pulisher
Nov 09, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.9%Here's What Happened - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 08, 2024
pulisher
Nov 08, 2024

Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlig - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Phathom Pharmaceuticals Reports Significant Revenue Growth - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Phathom Pharmaceuticals maintains $28 target, Buy rating - Investing.com

Nov 07, 2024
pulisher
Nov 06, 2024

Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Previ - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Jennison Associates LLC's Strategic Acquisition in Phathom Pharm - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 04, 2024
pulisher
Nov 01, 2024

Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96% - Yahoo Finance

Nov 01, 2024
pulisher
Oct 31, 2024

Phathom Pharmaceuticals (PHAT) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

PHAT SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action InvestigationPHAT - Marketscreener.com

Oct 30, 2024
pulisher
Oct 28, 2024

Phathom Pharmaceuticals to Report Third Quarter 2024 - GlobeNewswire

Oct 28, 2024
pulisher
Oct 28, 2024

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business - The Bakersfield Californian

Oct 28, 2024
pulisher
Oct 28, 2024

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 - StockTitan

Oct 28, 2024
pulisher
Oct 27, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the - GlobeNewswire

Oct 27, 2024
pulisher
Oct 27, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting - Yahoo Finance

Oct 27, 2024
pulisher
Oct 23, 2024

Where are the Opportunities in (PHAT) - Stock Traders Daily

Oct 23, 2024
pulisher
Oct 22, 2024

Some of the Gastroesophageal Reflux Disease Therapeutics market players are: - InsightAce Analytic

Oct 22, 2024
pulisher
Oct 20, 2024

Shareholders have faith in loss-making Phathom Pharmaceuticals (NASDAQ:PHAT) as stock climbs 6.6% in past week, taking one-year gain to 74% - Simply Wall St

Oct 20, 2024
pulisher
Oct 19, 2024

Creative Planning Has $278,000 Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World

Oct 19, 2024
pulisher
Oct 18, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 6.8%Time to Buy? - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Certain Common Stock of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-OCT-2024. - Marketscreener.com

Oct 17, 2024
pulisher
Oct 15, 2024

Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

A year in review: Phathom Pharmaceuticals Inc (PHAT)’s performance in the last year - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.4%Time to Sell? - MarketBeat

Oct 14, 2024
pulisher
Oct 14, 2024

PHAT’s 52-Week Rollercoaster: From $6.07 to $19.71 – What’s Next for Investors? - The InvestChronicle

Oct 14, 2024
pulisher
Oct 14, 2024

Financial Health Report: Phathom Pharmaceuticals Inc (PHAT)’s Ratios Tell a Tale - The Dwinnex

Oct 14, 2024
pulisher
Oct 13, 2024

Learn to Evaluate (PHAT) using the Charts - Stock Traders Daily

Oct 13, 2024
pulisher
Oct 11, 2024

A stock that deserves closer examination: Phathom Pharmaceuticals Inc (PHAT) - US Post News

Oct 11, 2024
pulisher
Oct 11, 2024

PHAT Stock Sees Decline of Approximately -13.44% in Last Five Days - Knox Daily

Oct 11, 2024
pulisher
Oct 10, 2024

PHAT Stock: A Comprehensive Analysis and Forecast - The InvestChronicle

Oct 10, 2024
pulisher
Oct 08, 2024

PHAT (Phathom Pharmaceuticals Inc) may reap gains as insiders became active recently - Knox Daily

Oct 08, 2024
pulisher
Oct 07, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.5%Here's What Happened - MarketBeat

Oct 07, 2024
pulisher
Oct 07, 2024

Daily Market Movement: Phathom Pharmaceuticals Inc (PHAT) Sees a -4.96 Decrease, Closing at 17.25 - The Dwinnex

Oct 07, 2024
pulisher
Oct 07, 2024

A new trading data show Phathom Pharmaceuticals Inc (PHAT) is showing positive returns. - SETE News

Oct 07, 2024

Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.50
price up icon 1.61%
$74.59
price down icon 1.14%
$370.49
price down icon 2.02%
$43.06
price down icon 0.76%
$215.00
price up icon 4.29%
$118.39
price down icon 1.93%
Cap:     |  Volume (24h):